MedTrace Logo

Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism

NCT03757923 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2018-11-29

No results posted yet for this study

Summary

To compare metformin with pioglitazone in improving menstrual irregularities and hyperandrogenism in women with PCOS so that an alternate and better treatment option will be available for hyperinsulinemia in pcos patients.

Conditions

  • Menstrual Irregularities
  • Hyperandrogenism

Interventions

DRUG

TAB METFORMIN

INSULIN SENSITIZING AGENTS

DRUG

TAB PIOGLITAZONE

INSULIN SENSITIZING AGENT

Sponsors & Collaborators

  • Dow University of Health Sciences

    lead OTHER

Principal Investigators

  • Bader F Zuberi, FCPS · Dow University of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-18
Primary Completion
2018-12-17
Completion
2019-01-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03757923 on ClinicalTrials.gov